Aptamers are chimerized with drug or antisense oligos or nanoparticles to generate targeted therapeutics for cancer. Aptamer chimerized siRNA rescues nonspecific delivery and, thereby, enhances the availability of siRNA to target cells. EpCAM RNA aptamer (EpApt or Ep) has potential for siRNA chimerization due to its secondary structure. Stathmin and survivin proteins are reported to aid oncogenicity in retinoblastoma (RB), breast cancer and other cancers. Thus, chimerization of EpCAM Apt with siRNA against survivin and stathmin, respectively, was performed by incorporating Locked Nucleic Acid (LNA) modification. The LNA-modified chimeric aptamers were stable until 96 h and got internalized into RB, WERI-Rb1 and breast cancer, MDAMB453 cell lines. The constructs were studied using the recombinant dicer enzyme for the siRNA generation. Quantitative polymerase chain reaction and immunofluorescence by microscopic analysis of chimeras in vitro exhibited silencing of stathmin and survivin in the RB and breast cancer model. The chimeric constructs showed significant inhibition of cell proliferation of breast cancer cells. Thus, LNA-modified aptamer-based siRNA delivery aids in cell targeting and necessitates further studies in animal models.
Get full access to this article
View all access options for this article.
References
1.
Urban-KleinB, WerthS, AbuharbeidS, CzubaykoF, and AignerA. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther, 12:461–466.
2.
PeerD, ZhuP, CarmanCV, LiebermanJ, and ShimaokaM. (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A, 104:4095–4100.
3.
DavisME, ZuckermanJE, ChoiCH, SeligsonD, TolcherA, et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464:1067–1070.
4.
HaoH, ZhenY, WangZ, ChenF, and XieX. (2013). A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol Int, 37:860–864.
5.
HussainAF, TurMK, and BarthS. (2013). An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing alphavbeta3 integrin. Nucleic Acid Ther, 23:203–212.
6.
NishimuraY, MiedaH, IshiiJ, OginoC, FujiwaraT, et al. (2013). Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J Nanobiotechnology, 11:19.
7.
ShigdarS, MacdonaldJ, O'ConnorM, WangT, XiangD, et al. (2013). Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel), 13:13624–13637.
8.
KanwarJR, ShankaranarayananJS, GurudevanS, and KanwarRK. (2014). Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov Today, 19:1309–1321.
9.
OravaEW, CicmilN, and GariepyJ. (2010). Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta, 1798:2190–2200.
10.
IresonCR, and KellandLR. (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther, 5:2957–2962.
11.
GiresO, KleinCA, and BaeuerlePA. (2009). On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer, 9: 143; author reply 143.
12.
GonzalezB, DenzelS, MackB, ConradM, and GiresO. (2009). EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells, 27:1782–1791.
13.
KrishnakumarS, MohanA, MallikarjunaK, VenkatesanN, BiswasJ, et al. (2004). EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci, 45:4247–4250.
14.
OstaWA, ChenY, MikhitarianK, MitasM, SalemM, et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res, 64:5818–5824.
15.
YamashitaT, BudhuA, ForguesM, and WangXW. (2007). Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res, 67:10831–10839.
16.
ShigdarS, LinJ, YuY, PastuovicM, WeiM, et al. (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci, 102:991–998.
17.
SongY, ZhuZ, AnY, ZhangW, ZhangH, et al. (2013). Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem, 85:4141–4149.
18.
SubramanianN, RaghunathanV, KanwarJR, KanwarRK, ElchuriSV, et al. (2012). Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis, 18:2783–2795.
19.
KanwarJR, RoyK, and KanwarRK. (2011). Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol, 46:459–477.
20.
LiL, XiangD, ShigdarS, YangW, LiQ, et al. (2014). Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine, 9:1083–1096.
21.
SubramanianN, KanwarJR, AthalyaP, JanakiramanN, KhetanV, et al. (2015). EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. J Biomed Sci, 22:4.
22.
SudhakarJ, VenkatesanN, LakshmananS, KhetanV, KrishnakumarS, et al. (2013). Hypoxic tumor microenvironment in advanced retinoblastoma. Pediatr Blood Cancer, 60:1598–1601.
23.
El DeebNM, and AbdelzaherE. (2014). Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression. Pathol Res Pract, 210:751–758.
24.
GuvencH, PavlyukovMS, JoshiK, KurtH, Banasavadi-SiddegowdaYK, et al. (2013). Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res, 19:631–642.
25.
KanwarJR, MahidharaG, RoyK, SasidharanS, KrishnakumarS, et al. (2015). Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine (Lond), 10:35–55.
26.
MiceliC, TejadaA, CastanedaA, and MistrySJ. (2013). Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther, 20:298–307.
27.
MitraM, KandalamM, SundaramCS, VermaRS, MaheswariUK, et al. (2011). Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Invest Ophthalmol Vis Sci, 52:5441–5448.
28.
NemunaitisJ. (2012). Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets, 16:631–634.
29.
BaqueroMT, HannaJA, NeumeisterV, ChengH, MolinaroAM, et al. (2012). Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer, 118:4660–4669.
30.
RoyK, KanwarRK, CheungCHA, FlemingCL, VeeduRN, et al. (2015). Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Adv, 5:29008–29016.
31.
DassieJP, LiuXY, ThomasGS, WhitakerRM, ThielKW, et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol, 27:839–849.
32.
SubramanianN, KanwarJR, KanwarRK, SreemanthulaJ, BiswasJ, et al. (2015). EpCAM aptamer-siRNA chimera targets and regress epithelial cancer. PLoS One, 10:e0132407.
33.
BellaousovS, ReuterJS, SeetinMG, and MathewsDH. (2013). RNAstructure: Web servers for RNA secondary structure prediction and analysis. Nucleic Acids Res, 41:W471–W474.
34.
ZukerM (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 31:3406–3415.
35.
SubramanianN, NavaneethakrishnanS, BiswasJ, KanwarRK, KanwarJR, et al. (2013). RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma. PLoS One, 8:e70422.
36.
BrownDA, KangSH, GryaznovSM, DeDionisioL, HeidenreichO, et al. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem, 269:26801–26805.
37.
CampbellMA, and WengelJ. (2011). Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev, 40:5680–5689.
38.
PrallF, MaletzkiC, and LinnebacherM. (2010). The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology, 56:553–555.
39.
MitraM, KandalamM, HarilalA, VermaRS, KrishnanUM, et al. (2012) EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis, 18:290–308.
40.
WenqiD, LiW, ShanshanC, BeiC, YafeiZ, et al. (2009). EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol, 135:1277–1285.
41.
YamashitaT, JiJ, BudhuA, ForguesM, YangW, et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 136:1012–1024.
42.
SubramanianN, KanwarJR, AkilandeswariB, KanwarRK, KhetanV, et al. (2015). Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chem Commun (Camb), 51:6940–6943.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
